Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

BACKGROUND: Current guidelines advise that rituximab or cyclophosphamide should be used for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), although few studies have examined the efficacy and safety of these agents in combination....

Descripción completa

Detalles Bibliográficos
Autores principales: McAdoo, Stephen P, Medjeral-Thomas, Nicholas, Gopaluni, Seerapani, Tanna, Anisha, Mansfield, Nicholas, Galliford, Jack, Griffith, Megan, Levy, Jeremy, Cairns, Thomas D, Jayne, David, Salama, Alan D, Pusey, Charles D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322443/
https://www.ncbi.nlm.nih.gov/pubmed/29462348
http://dx.doi.org/10.1093/ndt/gfx378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322443/
https://www.ncbi.nlm.nih.gov/pubmed/29462348
http://dx.doi.org/10.1093/ndt/gfx378

Ejemplares similares